CAM
LGND icon

Congress Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Congress Asset Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$209M Buy
659,911
+155,274
+31% +$36.6M 1.28% 9
2026
Q1 		$101M Buy
504,637
+24,574
+5% +$4.86M 0.72% 41
2025
Q4 		$90.8M Sell
480,063
-187,248
-28% -$36M 0.64% 52
2025
Q3 		$118M Buy
667,311
+19,370
+3% +$2.88M 0.79% 41
2025
Q2 		$73.7M Buy
647,941
+5,229
+0.8% +$559K 0.51% 84
2025
Q1 		$67.6M Buy
642,712
+21,230
+3% +$2.4M 0.51% 78
2024
Q4 		$66.6M Buy
621,482
+17,444
+3% +$1.97M 0.45% 87
2024
Q3 		$60.5M Buy
604,038
+17,414
+3% +$1.75M 0.41% 93
2024
Q2 		$49.4M Buy
+586,624
New +$46.7M 0.35% 96
2020
Q4 		– Sell
-51,897
Closed -$3.09M – 350
2020
Q3 		$3.09M Buy
51,897
+2,289
+5% +$156K 0.03% 204
2020
Q2 		$3.46M Buy
49,608
+1,050
+2% +$66.6K 0.04% 189
2020
Q1 		$2.2M Buy
48,558
+17,974
+59% +$1.02M 0.03% 211
2019
Q4 		$1.99M Sell
30,584
-10,393
-25% -$695K 0.02% 252
2019
Q3 		$2.54M Buy
40,977
+2,560
+7% +$161K 0.03% 249
2019
Q2 		$2.74M Buy
38,417
+2,588
+7% +$191K 0.03% 252
2019
Q1 		$2.81M Buy
35,829
+1,536
+4% +$116K 0.04% 241
2018
Q4 		$2.9M Sell
34,293
-72
-0.2% -$7.68K 0.04% 232
2018
Q3 		$5.88M Sell
34,365
-653
-2% -$98.4K 0.08% 164
2018
Q2 		$4.53M Buy
35,018
+1,623
+5% +$181K 0.06% 190
2018
Q1 		$3.44M Buy
33,395
+3,530
+12% +$349K 0.05% 219
2017
Q4 		$2.55M Buy
29,865
+6,052
+25% +$525K 0.04% 236
2017
Q3 		$2.02M Buy
23,813
+11,572
+95% +$916K 0.03% 257
2017
Q2 		$927K Buy
12,241
+1,977
+19% +$138K 0.02% 201
2017
Q1 		$678K Buy
10,264
+3,076
+43% +$202K 0.01% 214
2016
Q4 		$456K Buy
+7,188
New +$454K 0.01% 222

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Congress Asset Management's LGND Position: Q2 2026 in Review

Congress Asset Management increased its Ligand Pharmaceuticals (LGND) stake by 31% in Q2 2026, buying an estimated $36.6M and bringing the position to 659,911 shares worth $209M. The position accounts for 1.28% of the portfolio, ranked #9.

Congress Asset Management first reported a position in LGND in Q4 2016 and has held it in 25 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Congress Asset Management held 659,911 shares of Ligand Pharmaceuticals worth $209M as of Q2 2026.
  • Congress Asset Management bought 155,274 Ligand Pharmaceuticals shares in Q2 2026, an estimated $36.6M.
  • Ligand Pharmaceuticals made up 1.28% of Congress Asset Management's portfolio in Q2 2026, its #9 holding.
  • Congress Asset Management first reported a position in Ligand Pharmaceuticals in Q4 2016 and has held it in 25 quarters since.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Congress Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.